CL
PRTK

Croft-Leominster’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Croft-Leominster’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-10,000
Closed -$241K – 137
2017
Q2 		$241K Sell
10,000
-9,500
-49% -$210K 0.06% 121
2017
Q1 		$375K Buy
+19,500
New +$307K 0.09% 98
2016
Q4 		– Sell
-14,500
Closed -$188K – 125
2016
Q3 		$188K Buy
+14,500
New +$192K 0.05% 128

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Croft-Leominster's PRTK Position: Q3 2017 in Review

Croft-Leominster sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2017, closing a stake of 10,000 shares — an estimated $241K sold.

Croft-Leominster first reported a position in PRTK in Q3 2016 and held it in 3 quarters. The position peaked at $375K in Q1 2017. 133 funds tracked by Wall St. Rank hold PRTK as of Q3 2017.

  • Croft-Leominster reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Croft-Leominster sold 10,000 Paratek Pharmaceuticals, Inc. shares in Q3 2017, an estimated $241K.
  • Croft-Leominster first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2016 and held it in 3 quarters.
  • Croft-Leominster's Paratek Pharmaceuticals, Inc. position peaked at $375K in Q1 2017.
  • 133 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2017.

Based on Croft-Leominster's 13F filing for Q3 2017, filed 14 Nov 2017.